Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of subcutaneous SHR-1918 in patients with inadequately controlled hyperlipidemia
CTR20242242Phase 2Completed
- Sponsor
- Beijing Shengdi Pharmaceutical
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hyperlipidemia comparing SHR-1918 with Placebo (2 arms). Primary endpoint: Percent change from baseline in serum LDL-C at Week 24. Started Jun 2024; status: completed.
02
Drugs
SHR-1918
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on CTR20242242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242242.